

# *Welcome to today's FDA/CDRH Webinar*

*Thank you for your patience while additional time is  
provided for participants to join the call.*

**Please connect to the  
audio portion of the webinar now:**

**Dial: In U.S.: 888-323-9729**

**International: 1-212-547-0304**

**Passcode: 5890890**

**Conference Number: PWXW9364565**

# Dental Devices Premarket Submissions

**Malvina B. Eydelman, M.D., Director,**  
Office of Health Technology 1 (OHT1)

**Michael E. Adjodha, M.ChE., Acting Assistant Director**  
Restorative and Surgical Devices Team

**Srinivas “Nandu” Nandkumar, Ph.D., Acting Director**  
Division of Dental Devices

Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices  
(Office of Health Technology 1 (OHT1))  
Office of Product Evaluation and Quality (OPEQ)  
Center for Devices and Radiological Health (CDRH)

October 2, 2019

# Agenda

- Center for Devices and Radiological Health Reorganization
- Review Challenges and Opportunities for Dental Device 510(k) Submissions
  - 510(k) Process Overview
  - Dental Device Types
  - Dental Device Submission Challenges
  - Recommendations
  - Resources
- Postmarket Overview
  - Medical Device Reporting (MDR)
  - Medical Device Safety Action Plan
  - Safety Signal
  - Market Withdrawals and Recalls

# Objectives

During this webinar, the FDA will:

- Clarify the [premarket submissions](#) process, including what to submit and who to work with in the Center for Devices and Radiological Health's [Office of Product Evaluation and Quality \(OPEQ\)](#)
- Explain information to include in a 510(k) submission in order to avoid [refuse-to-accept \(RTA\)](#) designation
- Clarify [medical device reporting \(MDR\) requirements](#), including how to report and who should report (manufacturer, dentist, etc.)
- Discuss and answer questions from webinar participants about the premarket submissions for dental devices

# Center for Devices and Radiological Health (CDRH): Reorganization

**Malvina B. Eydelman, M.D.**

Director


Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices  
CDRH, FDA

# Center for Devices and Radiological Health Reorganization





- CDRH conducted phased implementation of a Center reorganization.
- CDRH reorganization includes adopting a Total Product Lifecycle (TPLC) model and other efforts to streamline and improve efficiency and to support employees' professional growth.
- Implementation timeline: March 2019 - October 2019


# CDRH Structure prior to Reorganization



# CDRH Structure After Reorg Implementation




# Office of Product Evaluation and Quality




- OC, ODE, OIR, and OSB reorganized into one Super Office (OPEQ)
- OPEQ has 9 offices



# Office of Product Evaluation and Quality (OPEQ)



# Office of Ophthalmic, Anesthesia, Respiratory, ENT, and Dental Devices (OHT1)



# OPEQ Design Features



- Working in teams
  - Team management approach
  - Teams within and across divisions
- Common management chain for compliance, premarket and surveillance programs
- Division is the lowest organizational structure
- Empowering staff by driving decision-making to lowest appropriate level
- Emphasis on professional development & work-life balance

# Value Added for You

- Improving our internal processes, coordination and communication → more straightforward & streamlined interactions with CDRH
- Consolidating our structure → provides you with a “one stop shop” in many cases
- Creating a more agile organization → better response to changing regulatory needs and new technologies

# Value Added for You

- Ensuring more consistent policy application across OPEQ → easier for you to know what to expect
- Streamlining decision making → more informed interactions with CDRH staff
- Focus on professional growth and creating a better work-life balance for our employees → increased longevity of your points of contact within the organization due to reduced staff turn-over


# Review Challenges and Opportunities for Dental Device 510(k) Submissions

Michael E. Adjodha, M.ChE.  
Acting Assistant Director,  
Restorative and Surgical Dental Devices Team

# Background

- Each person who wants **to market in the U.S. a medical device** intended for human use (for which a Premarket Approval application (PMA) is not required) must submit **a premarket notification submission (510(k))** to FDA **unless the device is exempt** from 510(k) requirements of the Federal Food, Drug, and Cosmetic Act (the FD&C Act).
- The 510(k) pathway is the **most common pathway** to market for medical devices
- A 510(k) is a premarket submission-made to the FDA to demonstrate that the device to be marketed is **as safe and effective**, that is, **substantially equivalent**, to a **legally marketed device** (Section 513(i) of FD&C Act)
- For more details about how to prepare a 510(k) submission, see the relevant guidance document:  
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/format-traditional-and-abbreviated-510ks>

# 510(k) Process Overview



## 510(k) Review Timeframe in FDA Days:\*

- **TRADITIONAL:** 90
- **ABBREVIATED:** 90
- **SPECIAL:** 30
- **THIRD PARTY:**30

## The FDA Review Clock:

- Does not begin if there is a user fee or eCopy issue.
- Starts when there are no user fee or eCopy issues.
- Pauses when submission is on Additional Information (AI) hold.
- Resumes upon receipt of response to AI Letter.
- Stops after recommendation letter is issued.

\*FDA Days are calculated as the number of calendar days between the date the 510(k) was received and the date of a MDUFA decision, excluding the days the submission was on hold for an AI request.

# Dental Device Types

Found in Part 872 of Title 21 of the Code of Federal Regulations (21 CFR 872)


[www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?CFRPart=872](http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?CFRPart=872)

- **Diagnostic Devices**
  - For example, caries detection device, radiography devices, etc.
- **Prosthetic Devices**
  - For example, C&B alloys and resins, composite resins, amalgam, cements, endosseous implants, root canal resins, bone grafting materials, impression materials, denture resins, endodontic materials, etc.
- **Surgical Devices**
  - For example, dental handpieces, ultrasonic scalars, bone plates, etc.
- **Therapeutic Devices**
  - For example, orthodontic appliances and treatment planning software, anti-snoring devices, etc.
- **Miscellaneous Devices**
  - For example, curing lamps, dental operative units, dental ceramics, prophy paste, toothbrushes, etc.

# General Observations

- **Predominate workload** involves **510(k)** submissions but also includes **Pre-Submissions**, **Premarket Approval (PMA) supplements** and **30-day notices**, **513(g)** submissions, and **Investigational Device Exemptions (IDEs)**
- **High volume** of 510(k) submissions
  - Significant percentage are from **small or foreign manufacturers**
- **High** first cycle **Refuse-to-Accept (RTA)** rate (81%) in CY 2018
- Average 510(k) clearances: 240+/year, down 10% in CY 2018

Number of 510(k) Clearances per CY



# General Observations



<b>Device types</b>	<b>Cleared in CY 2018</b>
Dental Abutments (NHA)	66
Endosseous Implants (DZE)	44
Composite Resins (EBF)	18
Aligners (NXC)	11
Snoring/Sleep Devices (LRK)	10
Dental Ceramics (EIH)	10
Resin Bonding Agent (KLE)	9
Dental Handpieces (EFB, EFA, EGS, EKX, EKY)	8
Denture Resin (EBI)	6
Orthodontic Software (PNN)	5

**Total cleared in 2018 = 219**

# General Observations



Device Type	Number of Submissions Accepted in CY 2018	Average FDA Review Days	Average Submitter Days (on hold)	Total Time to Decision
Orthodontic Software	2	90.5	96.5	187.0
Dental Handpieces	8	86.9	87.9	174.8
Snoring/Sleep Devices	12	89.2	54.2	143.4
Endosseous Implants	30	82.4	59.6	142.0
Dental Abutments	15	85.0	45.1	130.1

MDUFA IV				
FY18	FY19	FY20	FY21	FY22
124	120	116	112	108

# Refuse-to-Accept (RTA) Challenges



Common challenges include the following elements of the Acceptance Checklist for Traditional 510(k)s:

- **Device Description**

- Incomplete list and description of each device for which clearance is requested
- Lack of representative engineering drawings or images of the device
- Incomplete list (and 510(k) status) of all components of the device and any accessories to be marketed with the device
- Submission does not address recommendations of device-specific guidance nor provides alternative approach

- **Substantial Equivalence Discussion**

- Predicate device is used inconsistently; no justification provided if predicate not used in performance testing
- Lack of an discussion why any differences between your device and the predicate do not impact safety and effectiveness of *your* device

- **Proposed Labeling**

- Instructions for use and/or operator manual does not contain indications, a prescription statement (if applicable), and information for professional use, including instructions, hazards, warnings, precautions, contraindications, etc.

# RTA Challenges

- **Sterilization**
  - Incomplete information regarding sterilization and reprocessing, including method, validation, sterility assurance level (SAL), packaging, end user instructions, cleaning and disinfection methods
- **Biocompatibility**
  - Lack of biocompatibility testing or rationale on why such testing is not necessary
  - Incomplete material identification of all patient contacting components including all additives; additionally chemical identity should be complete
- **Performance data**
  - Test reports not provided
    - » Sometimes specifications given, no results are provided
  - Irrelevant or inadequate testing that fails to demonstrate how the data supports a finding of substantial equivalence
  - Performance data do not address recommendations of device-specific guidance or provide alternative approach

# Substantive Review Challenges and Opportunities



- **Support performance statements with data**
  - Any statement of **device performance** or indication that could **impact** the evaluation of **substantial equivalence** will be evaluated.
  - **New performance statements** will need to be appropriately supported **with data** (e.g. non-clinical performance data); some performance statements may necessitate **clinical data** (e.g. statements regarding **enhanced clinical outcomes**, etc.
- **Select appropriate primary predicate device**
  - Choose a primary predicate device that has the **closest intended use** (1<sup>st</sup>) and **technological characteristics** (2<sup>nd</sup>) to your device. Use the 510(k) Premarket Notification database: [www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm](http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm)
  - **Reference devices** can be used for **technological characteristics** (assuming no different Safety and Effectiveness questions) not found in your primary predicate device. See The 510(k) Program guidance (July 28, 2014): [www.fda.gov/regulatory-information/search-fda-guidance-documents/510k-program-evaluating-substantial-equivalence-premarket-notifications-510k](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/510k-program-evaluating-substantial-equivalence-premarket-notifications-510k)

# Substantive Review Challenges and Opportunities



- **Irrelevant or inadequate performance data to support a finding of substantial equivalence**
  - Search 510(k) summaries of predicates to determine what tests were relied upon for equivalence
  - Use relevant, recognized consensus standards for performance testing:  
[www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm](http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm)
  - See guidance on appropriate use of standards: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/appropriate-use-voluntary-consensus-standards-premarket-submissions-medical-devices>.
  - Search the guidance documents for appropriate guidance [www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/guidance-documents-medical-devices-and-radiation-emitting-products](http://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/guidance-documents-medical-devices-and-radiation-emitting-products)
- **Biocompatibility**
  - Conduct appropriate testing and/or provide tox risk analysis for why testing is not necessary. See 2016 guidance: [www.fda.gov/regulatory-information/search-fda-guidance-documents/use-international-standard-iso-10993-1-biological-evaluation-medical-devices-part-1-evaluation-and](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-international-standard-iso-10993-1-biological-evaluation-medical-devices-part-1-evaluation-and)

# Substantive Review Challenges and Opportunities



- **End user sterilization/reprocessing**
  - Provide **validated instructions** that would allow the user to **properly reprocess the device**.
  - See:
    - 2016 sterility guidance [www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-and-review-sterility-information-premarket-notification-510k-submissions-devices-labeled](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-and-review-sterility-information-premarket-notification-510k-submissions-devices-labeled)
    - 2015 reprocessing guidance [www.fda.gov/regulatory-information/search-fda-guidance-documents/reprocessing-medical-devices-health-care-settings-validation-methods-and-labeling](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/reprocessing-medical-devices-health-care-settings-validation-methods-and-labeling)
- **Content of 510(k) summaries should:**
  - **Be complete** per 21 CFR 807.92
  - Include a **comparison of indications and technological characteristics** and why any differences do not affect substantial equivalence
  - Include a brief description of the **tests relied upon** for SE determination
  - Avoid absolute statement that the device is “safe and effective”; 510(k) process is based on substantial equivalence (“**as safe and as effective**”) to a predicate
  - Use the **same Indications** for Use (IFU) in Summary as that in the IFU statement
  - **Not contain trade secret** or confidential commercial information, as it will be posted on the FDA’s public database [www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm](http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm)
  - Follow **good examples** of 510(k) Summaries in the database

# Best Practices

- Follow and include a copy of **RTA checklist** in your submission [www.fda.gov/medical-devices/premarket-notification-510k/acceptance-checklists-510ks](http://www.fda.gov/medical-devices/premarket-notification-510k/acceptance-checklists-510ks)
- **When responding to RTA (or any deficiency)**, please indicate or highlight **how and where** the deficiencies have been addressed
  - See deficiency guidance: [www.fda.gov/regulatory-information/search-fda-guidance-documents/developing-and-responding-deficiencies-accordance-least-burdensome-provisions](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/developing-and-responding-deficiencies-accordance-least-burdensome-provisions)
- Choose an **appropriate predicate device**
  - Search the 510(k) Premarket Notification database [www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm](http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm)
  - See The 510(k) Program guidance [www.fda.gov/regulatory-information/search-fda-guidance-documents/510k-program-evaluating-substantial-equivalence-premarket-notifications-510k](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/510k-program-evaluating-substantial-equivalence-premarket-notifications-510k)

# Best Practices

- Include **summary tables of the tests** conducted, even if you include full test reports
  - <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommended-content-and-format-non-clinical-bench-performance-testing-information-premarket>
- Clearly **explain the differences** between your device and the predicate device(s) and **why the differences do not affect** the safety or effectiveness of your device
- Please provide **text-searchable PDF** files
- **Proofread** final submission
  - Ensure **consistency** throughout submission
- Please include your **direct contact information** (email and direct phone line); you may also identify **alternative contacts**, if applicable.

# Premarket Resources

- Refer to FDA's **Device Advice** website  
[www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance](http://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance)
- **CDRH Learn**  
[www.fda.gov/training-and-continuing-education/cdrh-learn](http://www.fda.gov/training-and-continuing-education/cdrh-learn)
- Division of Industry and Consumer Education (**DICE**)  
[www.fda.gov/DICE](http://www.fda.gov/DICE)
- The **510(k) Program** and **Content** guidances
  - [www.fda.gov/regulatory-information/search-fda-guidance-documents/510k-program-evaluating-substantial-equivalence-premarket-notifications-510k](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/510k-program-evaluating-substantial-equivalence-premarket-notifications-510k)
  - <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/format-traditional-and-abbreviated-510ks>
- Consider **Pre-Submissions** for feedback; See the guidance on the Q-Submission Program, [www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program)
- Contact the **review division** for additional questions

# Reminders

- **Unsupported indications or performance statements** and the selection of **appropriate predicate devices** continue to present the most significant challenges for clearance of dental devices
- Using **relevant guidance/standards** and understanding **the differences between the subject device and predicate device** and clearly articulating and demonstrating how these **do not affect safety and effectiveness** is key to overcoming many deficiencies.

# Postmarket Overview

Srinivas “Nandu” Nandkumar, Ph.D.  
Acting Director, Division of Dental Devices

# CDRH Vision Statement

*“Patients in the U.S. have access to high-quality, safe, and effective medical devices of public health importance first in the world. The U.S. is the world’s leader in regulatory science, medical device innovation and manufacturing, and radiation-emitting product safety. **U.S. post-market surveillance quickly identifies poorly performing devices, accurately characterizes real-world performance, and facilitates device approval or clearance. Devices are legally marketed in the U.S. and remain safe, effective, and of high-quality.** Consumers, patients, their caregivers, and providers have access to understandable science-based information about medical devices and use this information to make health care decisions.”*

[www.fda.gov/about-fda/center-devices-and-radiological-health/cdrh-mission-vision-and-shared-values](http://www.fda.gov/about-fda/center-devices-and-radiological-health/cdrh-mission-vision-and-shared-values)

# Medical Device Reporting (MDR)

- Reports of suspected device-associated deaths, serious injuries, and malfunctions submitted to FDA
- Mandatory reporting by manufacturers, device user facilities, and importers
- Voluntary reporting by health care professionals, patients, and consumers

[www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems](http://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems)

# FDA's Medical Device Safety Action Plan (November 2018)

*“Ensuring that the FDA is consistently first among the world’s regulatory agencies to identify and act upon safety signals related to medical devices.”*

[www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-and-jeff-shuren-md-director-center-devices-and-2](https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-and-jeff-shuren-md-director-center-devices-and-2)

# What is a Safety Signal?

- A signal represents information which:
  - may arise from one or more sources
  - suggests a new potentially causal association, or a new aspect of a known association, between a medical device and an event or set of related events
  - might justify or require further evaluation and/or action by the Center
- Examples:
  - Unanticipated/unlabeled adverse events of clinical significance
  - Increase in the severity or rate of a labeled/known event
  - New product failure mechanism/mode causing patient injury
  - Poor outcomes due to inadequate training, inadequate instructions or human factor concerns
  - New risks introduced by off-label use

# Signal Detection

- Medical Device Reports (MDR)<sup>1</sup>
- Post Approval Studies<sup>2</sup>
- 522 Postmarket Surveillance Studies<sup>3</sup>
- Device annual reports
- Consumer complaints

<sup>1</sup> [www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems](http://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems)


<sup>2</sup> [www.fda.gov/devicepostapproval](http://www.fda.gov/devicepostapproval)

<sup>3</sup> [www.fda.gov/522studies](http://www.fda.gov/522studies)

# Signal Refinement

- Information Gathering
  - Communication with manufacturer as soon as possible
  - Literature Search
  - Medical Device Report (MDR) Analysis
  - Interim results from ongoing postmarket studies
- Assessment of Signal by Signal Team
  - Likelihood, magnitude, of event
  - Causal relationship
  - Potential for mitigation or alternative therapies

# Action Plan



<sup>1</sup> <https://www.fda.gov/medical-devices/medical-device-safety>

<sup>2</sup> <https://www.fda.gov/regulatory-information/search-fda-guidance-documents>

<sup>3</sup> <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm>

# Market Withdrawals and Recalls

- Market Withdrawal: when a manufacturer makes a business decision to withdraw a device from the market for any reason
- Recall: when a manufacturer takes a correction or removal action to address a problem with a medical device, in the field, that violates FDA regulations.
  - Correction vs. removal actions
  - Classification of recalls based on risk to health
- Posted in the online Medical Device Recall Database:  
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm>

# Questions?

Division of Industry and Consumer Education:  
[DICE@fda.hhs.gov](mailto:DICE@fda.hhs.gov)

Slide Presentation, Transcript and Webinar Recording  
will be available at:

<http://www.fda.gov/training/cdrhlearn>

Under Heading: Specialty Technical Topics;  
Subheading: Device Specific Topics

Please complete a short survey about your FDA CDRH  
webinar experience. The survey can be found at  
[www.fda.gov/CDRHWebinar](http://www.fda.gov/CDRHWebinar)  
immediately following the conclusion of the live  
webinar.